Humoral responses to oxidized low-density lipoprotein and related bacterial antigens after pneumococcal vaccine

Translational Research

Volumn 150, Issue 3, 2007, Pages 172-179

  Nguyen, John T ^a   Myers, Nicollette ^a   Palaia, Jana ^a   Georgopoulos, Angeliki ^a   Rubins, Jeffrey B ^a   Janoff, Edward N ^b  

^a UNIVERSITY OF MINNESOTA MEDICAL SCHOOL   (United States)

^b UNIVERSITY OF COLORADO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BACTERIAL ANTIGEN; IMMUNOGLOBULIN A; IMMUNOGLOBULIN G; IMMUNOGLOBULIN M; LIPID; OXIDIZED LOW DENSITY LIPOPROTEIN; PHOSPHORYLCHOLINE; PNEUMOCOCCUS VACCINE; PROTEIN ANTIBODY;

ADULT; ANTIBODY PRODUCTION; ANTIGEN ANTIBODY REACTION; ARTICLE; ATHEROGENESIS; ATHEROSCLEROSIS; BACTERIAL MEMBRANE; CONTROLLED STUDY; DIET RESTRICTION; FEMALE; HUMAN; HUMAN EXPERIMENT; HUMORAL IMMUNITY; IMMUNIZATION; LIPID BLOOD LEVEL; LIPID TRANSPORT; MACROPHAGE; MALE; NORMAL HUMAN; PRIORITY JOURNAL; SMOKING; STATISTICAL SIGNIFICANCE; TREATMENT DURATION; VACCINATION;

EID: 34548182302     PISSN: 19315244     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.trsl.2007.04.001     Document Type: Article

References (49)

1. Salonen J.T., Yla-Herttuala S., Yamamoto R., Butler S., Korpela H., Salonen R., et al. Autoantibody against oxidised LDL and progression of carotid atherosclerosis. Lancet 339 (1992) 883-887
2. Maggi E., Finardi G., Poli M., Bollati P., Filipponi M., Stefano P.L., et al. Specificity of autoantibodies against oxidized LDL as an additional marker for atherosclerotic risk. Coron Artery Dis 4 (1993) 1119-1122
3. Maggi E., Chiesa R., Melissano G., Castellano R., Astore D., Grossi A., et al. LDL oxidation in patients with severe carotid atherosclerosis. A study of in vitro and in vivo oxidation markers. Arterioscler Thromb 14 (1994) 1892-1899
4. Puurunen M., Manttari M., Manninen V., Tenkanen L., Alfthan G., Ehnholm C., et al. Antibody against oxidized low-density lipoprotein predicting myocardial infarction. Arch Intern Med 154 (1994) 2605-2609
5. Bergmark C., Wu R., de Faire U., Lefvert A.K., and Swedenborg J. Patients with early-onset peripheral vascular disease have increased levels of autoantibodies against oxidized LDL. Arterioscler Thromb Vasc Biol 15 (1995) 441-445
6. Tsimikas S., Palinski W., and Witztum J.L. Circulating autoantibodies to oxidized LDL correlate with arterial accumulation and depletion of oxidized LDL in LDL receptor-deficient mice. Arterioscler Thromb Vasc Biol 21 (2001) 95-100
7. Shaw P.X., Horkko S., Chang M.K., Curtiss L.K., Palinski W., Silverman G.J., et al. Natural antibodies with the T15 idiotype may act in atherosclerosis, apoptotic clearance, and protective immunity. J Clin Invest 105 (2000) 1731-1740
8. Yla-Herttuala S., Palinski W., Butler S.W., Picard S., Steinberg D., and Witztum J.L. Rabbit and human atherosclerotic lesions contain IgG that recognizes epitopes of oxidized LDL. Arterioscler Thromb 14 (1994) 32-40
9. Pech-Amsellem M.A., Myara I., Storogenko M., Demuth K., Proust A., and Moatti N. Enhanced modifications of low-density lipoproteins (LDL) by endothelial cells from smokers: a possible mechanism of smoking-related atherosclerosis. Cardiovasc Res 31 (1996) 975-983
10. Sackett D.L., Gibson R.W., Bross I.D., and Pickren J.W. Relation between aortic atherosclerosis and the use of cigarettes and alcohol. An autopsy study. N Engl J Med 279 (1968) 1413-1420
11. Kannell W.B. Update on the role of cigarette smoking in coronary artery disease. Am Heart J 101 (1981) 319-328
12. Heitzer T., Yla-Herttuala S., Luoma J., Kurz S., Munzel T., Just H., et al. Cigarette smoking potentiates endothelial dysfunction of forearm resistance vessels in patients with hypercholesterolemia. Role of oxidized LDL. Circulation 93 (1996) 1346-1353
13. Sherer Y., Tenenbaum A., Praprotnik S., Shemesh J., Blank M., Fisman E.Z., et al. Coronary artery disease but not coronary calcification is associated with elevated levels of cardiolipin, beta-2-glycoprotein-I, and oxidized LDL antibodies. Cardiology 95 (2001) 20-24
14. Binder C.J., Horkko S., Dewan A., Chang M.K., Kieu E.P., Goodyear C.S., et al. Pneumococcal vaccination decreases atherosclerotic lesion formation: molecular mimicry between Streptococcus pneumoniae and oxidized LDL. Nat Med 9 (2003) 736-743
15. Zhou X., Caligiuri G., Hamsten A., Lefvert A.K., and Hansson G.K. LDL immunization induces T-cell-dependent antibody formation and protection against atherosclerosis. Arterioscler Thromb Vasc Biol 21 (2001) 108-114
16. Palinski W., Miller E., and Witztum J.L. Immunization of low density lipoprotein (LDL) receptor-deficient rabbits with homologous malondialdehyde-modified LDL reduces atherogenesis. Proc Natl Acad Sci U S A 92 (1995) 821-825
17. Freigang S., Horkko S., Miller E., Witztum J.L., and Palinski W. Immunization of LDL receptor-deficient mice with homologous malondialdehyde-modified and native LDL reduces progression of atherosclerosis by mechanisms other than induction of high titers of antibodies to oxidative neoepitopes. Arterioscler Thromb Vasc Biol 18 (1998) 1972-1982
18. Palinski W., and Witztum J.L. Immune responses to oxidative neoepitopes on LDL and phospholipids modulate the development of atherosclerosis. J Intern Med 247 (2000) 371-380
19. Ameli S., Hultgardh-Nilsson A., Regnstrom J., Calara F., Yano J., Cercek B., et al. Effect of immunization with homologous LDL and oxidized LDL on early atherosclerosis in hypercholesterolemic rabbits. Arterioscler Thromb Vasc Biol 16 (1996) 1074-1079
20. Gillotte K.L., Horkko S., Witztum J.L., and Steinberg D. Oxidized phospholipids, linked to apolipoprotein B of oxidized LDL, are ligands for macrophage scavenger receptors. J Lipid Res 41 (2000) 824-833
21. Chang B., and Casali P. A sequence analysis of human germline Ig VH and VL genes. The CDR1s of a major proportion of VH, but not VL, genes display a high inherent susceptibility to amino acid replacement. Ann N Y Acad Sci 764 (1995) 170-179
22. Friedberg D.N., Stenson S.M., Orenstein J.M., Tierno P.M., and Charles N.C. Microsporidial keratoconjunctivitis in acquired immunodeficiency syndrome. Arch Ophthalmol 108 (1990) 504-508
23. Jeon Y.E., Seo C.W., Yu E.S., Lee C.J., Park S.G., and Jang Y.J. Characterization of human monoclonal autoantibody Fab fragments against oxidized LDL. Mol Immunol 44 (2007) 827-836
24. Snapper C.M., Shen Y., Khan A.Q., Colino J., Zelazowski P., Mond J.J., et al. Distinct types of T-cell help for the induction of a humoral immune response to Streptococcus pneumoniae. Trends Immunol 22 (2001) 308-311
25. Centers for Disease Control and Prevention. Prevention of pneumococcal disease among infants and young children: recommendations of the Advisory Committee on Immunization Practices. MMWR Morb Mortal Wkly Rep 49 (2000) 1-35
26. Vióarsson G., Jónsdóttir I., Jónsson S., and Valdimarsson H. Opsonization and antibodies to capsular and cell wall polysaccharides of Streptococcus pneumoniae. J Infect Dis 170 (1994) 592-595
27. Goldblatt D., Levinsky R.J., and Turner M.W. Role of cell wall polysaccharide in the assessment of IgG antibodies to the capsular polysaccharides of Streptococcus pneumoniae in childhood. J Infect Dis 166 (1992) 632-634
28. Frasch C.E., and Concepcion N.F. Specificity of human antibodies reactive with pneumococcal C polysaccharide. Infect Immun 68 (2000) 2333-2337
29. Musher D.M., Watson D.A., and Baughn R.E. Does naturally acquired IgG antibody to cell wall polysaccharide protect human subjects against pneumococcal infection?. J Infect Dis 161 (1990) 736-740
30. Såorenson U.B.S., and Henrichsen J. C-polysaccharide in a pneumococcal vaccine. APMIS 92 (1984) 351-356
31. Carson P.J., Schut R.L., Simpson M.L., O'Brien J., and Janoff E.N. Antibody class and subclass responses to pneumococcal polysaccharides following immunization of human immunodeficiency virus-infected patients. J Infect Dis 172 (1995) 340-345
32. Ekdahl K., Braconier J.H., and Svanborg C. Impaired antibody response to pneumococcal capsular polysaccharides and phosphorylcholine in adult patients with a history of bacteremic pneumococcal infection. Clin Infect Dis 25 (1997) 654-660
33. Romero-Steiner S., Libutti D., Pais L.B., et al. Standardization of an opsonophagocytic assay for the measurement of functional antibody activity against Streptococcus pneumoniae using differentiated HL-60 cells. Clin Diagn Lab Immunol 4 (1997) 415-422
34. Janoff E.N., Fasching C., Ojoo J.C., O'Brien J., and Gilks C.F. Responsiveness of human immunodeficiency virus type 1-infected Kenyan women with or without prior pneumococcal disease to pneumococcal vaccine. J Infect Dis 175 (1997) 975-978
35. Lopez A.D., and Murray C.C. The global burden of disease, 1990-2020. Nat Med 4 (1998) 1241-1243
36. Murray C.J., and Lopez A.D. Mortality by cause for eight regions of the world: Global Burden of Disease Study. Lancet 349 (1997) 1269-1276
37. Shaw P.X., Goodyear C.S., Chang M.K., Witztum J.L., and Silverman G.J. The autoreactivity of anti-phosphorylcholine antibodies for atherosclerosis-associated neo-antigens and apoptotic cells. J Immunol 170 (2003) 6151-6157
38. Stemme S., Faber B., Holm J., Wiklund O., Witztum J.L., and Hansson G.K. T lymphocytes from human atherosclerotic plaques recognize oxidized low density lipoprotein. Proc Natl Acad Sci U S A 92 (1995) 3893-3897
39. Rose N., and Afanasyeva M. Autoimmunity: busting the atherosclerotic plaque. Nat Med 9 (2003) 641-642
40. Musher D.M., Chapman A.J., Goree A., Jonsson S., Briles D., and Baugh R.E. Natural and vaccine-related immunity to Streptococcus pneumoniae. J Infect Dis 154 (1986) 245-256
41. Damoiseaux J., Rijkers G., and Tervaert J.W. Pneumococcal vaccination does not increase circulating levels of IgM antibodies to oxidized LDL in humans and therefore precludes an anti-atherogenic effect. Atherosclerosis 190 (2007) 10-11
42. Jackson L.A., Neuzil K.M., Yu O., Benson P., Barlow W.E., Adams A.L., et al., Vaccine Safety Datalink. Effectiveness of pneumococcal polysaccharide vaccine in older adults. N Engl J Med 348 (2003) 1747-1755
43. Erkkila A.T., Narvanen O., Lehto S., Uusitupa M.I., and Yla-Herttuala S. Autoantibodies against oxidized low-density lipoprotein and cardiolipin in patients with coronary heart disease. Arterioscler Thromb Vasc Biol 20 (2000) 204-209
44. Schenkein H.A., Berry C.R., Purkall D., Burmeister J.A., Brooks C.N., and Tew J.G. Phosphorylcholine-dependent cross-reactivity between dental plaque bacteria and oxidized low-density lipoproteins. Infect Immun 69 (2001) 6612-6617
45. Schettino E.W., Chai S.K., Kasaian M.T., Schroeder Jr. H.W., and Casali P. VHDJH gene sequences and antigen reactivity of monoclonal antibodies produced by human B-1 cells: evidence for somatic selection. J Immunol 158 (1997) 2477-2489
46. Brown M., Schiffman G., and Rittenberg M.B. Subpopulations of antibodies to phosphocholine in human serum. J Immunol 132 (1984) 1323-1328
47. Chang M.K., Binder C.J., Miller Y.I., Subbanagounder G., Silverman G.J., Berliner J.A., et al. Apoptotic cells with oxidation-specific epitopes are immunogenic and proinflammatory. J Exp Med 200 (2004) 1359-1370
48. Caligiuri G., Nicoletti A., Poirier B., and Hansson G.K. Protective immunity against atherosclerosis carried by B cells of hypercholesterolemic mice. J Clin Invest 109 (2002) 745-753
49. Reardon C.A., Miller E.R., Blachowicz L., Lukens J., Binder C.J., Witztum J.L., et al. Autoantibodies to OxLDL fail to alter the clearance of injected OxLDL in apolipoprotein E-deficient mice. J Lipid Res 45 (2004) 1347-1354